'Highest risk-highest benefit' strategy: a pragmatic, cost-effective approach to targeting use of PCSK9 inhibitor therapies.

Lieven Annemans ; Chris J Packard ; Andrew Briggs ORCID logo ; Kausik K Ray ; (2018) 'Highest risk-highest benefit' strategy: a pragmatic, cost-effective approach to targeting use of PCSK9 inhibitor therapies. EUROPEAN HEART JOURNAL, 39 (27). pp. 2546-2550. ISSN 0195-668X DOI: 10.1093/eurheartj/ehx710
Copy
Item Type Article
Elements ID 136913
Date Deposited 25 Oct 2019 13:21

Explore Further

picture_as_pdf
Highest risk-highest benefit strategy a pragmatic, cost-effective approach to targeting use of PCSK9 inhibitor therapies.pdf
subject
Published Version
Available under Creative Commons: Attribution 3.0
View Download

Atom BibTeX OpenURL ContextObject in Span Multiline CSV OpenURL ContextObject Dublin Core Dublin Core MPEG-21 DIDL Data Cite XML EndNote HTML Citation JSON MARC (ASCII) MARC (ISO 2709) METS MODS RDF+N3 RDF+N-Triples RDF+XML RIOXX2 XML Reference Manager Refer Simple Metadata ASCII Citation EP3 XML
Export

Downloads